HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use EUCRISA safely and effectively. See full prescribing information for EUCRISA. EUCRISA® (crisaborole) ointment, for topical use Initial U.S. Approval: 2016 RECENT MAJOR CHANGES
INDICATIONS AND USAGEEUCRISA is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. (1) DOSAGE AND ADMINISTRATIONDOSAGE FORMS AND STRENGTHSOintment, 2%. (3) CONTRAINDICATIONSKnown hypersensitivity to crisaborole or any component of the formulation. (4) WARNINGS AND PRECAUTIONSHypersensitivity reactions: If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy. (5.1) ADVERSE REACTIONSThe most common adverse reaction occurring in ≥1% in subjects is application site pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 4/2020 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
EUCRISA Highlights (crisaborole)
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at(800) 438-1985.
(800)-332-1088.